1. A First‐in‐Human Clinical Study With TRV734, an Orally Bioavailable G‐Protein–Biased Ligand at the μ‐Opioid Receptor. Issue 2 (8th July 2019) Authors: James, Ian E.; Skobieranda, Franck; Soergel, David G.; Ramos, Kimberly A.; Ruff, Dennis; Fossler, Michael J. Journal: Clinical pharmacology in drug development Issue: Volume 9:Issue 2(2020) Page Start: 256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes. (30th June 2011) Authors: Scully, Michael S.; Ort, Tatiana A.; James, Ian E.; Bugelski, Peter J.; Makropoulos, Dorie A.; Deutsch, Heather A.; Pieterman, Elsbet J.; van den Hoek, Anita M.; Havekes, Louis M.; duBell, William H.; Wertheimer, Joshua D.; Picha, Kristen M. Other Names: Yorek Mark A. Academic Editor. Journal: Experimental diabetes research Issue: Volume 2011(2011) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Two‐Part Phase 1 Multiple‐Ascending‐Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults. Issue 1 (3rd September 2021) Authors: Ramos, Kimberly A.; James, Ian E.; Skobieranda, Franck; Soergel, David G.; Ruff, Dennis; Fossler, Michael J. Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 1(2022) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗